44th Annual J.P. Morgan Healthcare Conference
Logotype for Henry Schein Inc

Henry Schein (HSIC) 44th Annual J.P. Morgan Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Henry Schein Inc

44th Annual J.P. Morgan Healthcare Conference summary

17 Nov, 2026

Leadership transition and profile

  • Fred Lowery, currently EVP and President of Laboratory Products and BioProduction at Thermo Fisher Scientific, was named CEO effective March 2; he brings 20+ years of healthcare experience and a record of scaling complex businesses.

  • Succession considered internal and external candidates, with an orderly transition as a priority.

  • Leadership and the board expressed confidence in Lowery’s fit to advance BOLD+1 and value creation; culture and values remain differentiators, with momentum strong after the cyber incident.

Operating performance and market outlook

  • 2025 sales growth accelerated across reportable segments, with stable dental conditions, steady medical patient traffic and market-share gains across most businesses; Specialty Products and Technology benefited from new offerings, while Distribution gained share.

  • Dental conditions were stable to slightly positive, with pricing pressure as purchasing shifted from national brands to private labels.

  • Growth drivers include share gains, a broad portfolio, omnichannel execution and increased sales-force investment; mid-market and large DSOs are growing faster than independent practices.

Financial highlights and value creation

  • A $200M+ operating-income improvement plan targets lower global SG&A and higher gross margins; net benefits are expected in 2026, with full impact by 2027.

  • BOLD+1 targets 60% of operating income from high-growth, high-margin and owned-brand products by 2027; the plan also specifies over 50% of non-GAAP operating income from high-growth, high-margin businesses plus more than 10% from corporate brands.

  • Strong cash flow supported strategic investment, including accelerated share repurchases; buybacks were described as accretive to EPS.

  • From 2017–2024, non-GAAP operating income CAGR was 3.6% and non-GAAP diluted EPS CAGR was 6.2%; the 2023 cyber incident was estimated to reduce operating income by $120M–$130M and EPS by $0.70–$0.75.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Henry Schein